Comparative Pharmacology
Head-to-head clinical analysis: ANNOVERA versus HALOETTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANNOVERA versus HALOETTE.
ANNOVERA vs HALOETTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive containing segesterone acetate, a progestin, and ethinyl estradiol, an estrogen. Segesterone acetate suppresses gonadotropin release, preventing ovulation; ethinyl estradiol contributes to contraceptive efficacy by stabilizing the endometrium and inhibiting gonadotropin secretion.
Etonogestrel is a progestin that suppresses gonadotropin release, inhibiting ovulation and increasing cervical mucus viscosity.
One vaginal ring inserted and left in place for 3 weeks, followed by a 1-week ring-free interval. Each ring releases ethinyl estradiol 0.024 mg/day and segesterone acetate 0.15 mg/day over 21 days.
One 13.9 mg subcutaneous etonogestrel implant inserted into the inner side of the non-dominant upper arm for contraception; effective for 3 years.
None Documented
None Documented
Terminal half-life of etonogestrel (ENG): ~25 hours; ethinylestradiol (EE): ~12 hours; steady-state achieved after 7-14 days.
Terminal elimination half-life is approximately 1.3–1.7 hours (mean 1.5 hours). The short half-life supports continuous intravenous infusion for sustained sedation in critical care.
Renal: ~60% as metabolites; fecal: ~35% as metabolites; biliary: minor.
Renal excretion of metabolites accounts for approximately 85–90% of elimination; biliary/fecal excretion accounts for 10–15%.
Category C
Category C
Contraceptive
Contraceptive